In addition to crystallization, computational, and site-directed mutagenesis studies, in-vitro 85 random mutagenesis is known to be a powerful tool to get insights into the structure-function 86 relationship of proteins, even of membrane transporters (23) (24) (25) (26) . This approach may help to 87 locate beside targets of potential efflux pump inhibitors (EPIs) (27,28) binding sites and the 88 translocation pathways of drugs and other substrates. 89 In the present study, we screened a library of highly clarithromycin-resistant AcrB variants 90 derived from chromosome-based in-vitro random mutagenesis of the periplasmic porter 91 domain, and identified a number of AcrB mutations with a divergent impact on the 92 susceptibility to different drugs and chemicals. We here report that mutations at residues I38 93 and I671 which appear to constitute a narrow in the lower part of the AcrB periplasmic porter 94 domain lead to this divergent resistance phenotype with unchanged or even enhanced AcrB 95 associated resistance to many drugs of higher molecular weight but considerably increased 96 susceptibility to drugs with lower molecular weight. These findings demonstrate new pump 97 substrate specificity determinants within the lower porter domain in addition to previously 98 described at the proximal and distal AcrB binding pocket. Germany) according to the manufacturer's protocol. Briefly, the gene region corresponding to 130 the periplasmic loop 1 was replaced by an rpsL-neo cassette, which was exchanged in a second 131 step by a PCR product amplified from genomic DNA of the I38F single mutant as template (using 132 proof reading enzyme Q5® polymerase, New England Biolabs, Franfurt, Germany; forward 133 primer: 5'-AAACAGGAGCCGTTAAGACA-3', reverse primer: 5'-CGGAAGTTCTGCAGGAACAG-3').
134
The counter-selected mutants with replaced rpsL-neo cassette were confirmed by sequencing.
135
The oligonucleotides used for amplification of the rpsL-neo cassette with homology arms 136 adjacent to the acrB gene region corresponding to the periplasmic loop 1 were reported 137 previously (27 derived from the parental wild-type 3-AG100 E.coli ( . Notably, all of the investigated non-DR (Table 3, Table S2 ) mutants harbor at least one 304 mutation that might affect the binding capacity of the PBP (with two exceptions both containing 305 a substitution at P224 located at the intermonomer connecting loop), and those mutations, 
ΔAcrB
AcrB deficient 3-AG100, derived by deleting total acrB, Schuster et al, 2014 (27) .
I38F
Chromosomal AcrB variant of 3-AG100 derived from in-vitro random mutagenesis, this study
I671T
Chromosomal AcrB variant of 3-AG100 derived from in-vitro random mutagenesis, this study I671TΔAcrB AcrB (::rpsLneo) knockout strain derived from AcrB variant I671T, this study.
I38F/I671T
Chromosomal AcrB variant of 3-AG100 derived by sit-directed mutagenesis, this study.
pAcrB wt pET24a-acrB wt , kindly provided from Klaas Martinus Pos b .
pAcrB-I38F From plasmid-based site-directed mutagenesis of acrB using pAcrB wt , this study.
pAcrB-I671T
From plasmid-based site-directed mutagenesis of acrB using pAcrB wt , this study. figure 2) ; pyronin Y accumulation was calculated from the quenching effect (decrease of fluorescence) caused by intercellular accumulation at 10 min (time of the quenching maximum reached from ΔAcrB).
b MIC changes ≥ 4-fold compared to parental strain 3-AG100 depicted in bold and underlined; nd, not determined.
c With ethidium and berberine the solubility of the dyes in broth was limited to the MIC detected with parental strain 3-AG100.
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